Category Archives: Stem Cell Clinic


DDP and Austin Aries Reportedly Pitching Stem Cell Venture to AEW | 411MANIA – 411mania.com

Diamond Dallas Page and Austin Aries had business at last nights AEW according to a new report, but not the kind you might immediately think of. As noted last night, DDP and Aries were seen entering the area at last nights episode in Atlanta.

According to BodySlam.net, the two were there because theyre part of a stem cell treatment venture. They were there to pitch the idea to AEW in hopes that the company would buy into the venture. Stem Cell therapy has become increasingly popular among wrestlers to deal with injury issues over the past several years, and Aries is one of several people (along with Ken Shamrock, Rob Van Dam and others) to make regular mention of the BioXcellerator stem cell therapy clinic.

DDP has been a semi-regular on AEW, making several appearances on Dynamite over the past few months.

Go here to read the rest:
DDP and Austin Aries Reportedly Pitching Stem Cell Venture to AEW | 411MANIA - 411mania.com

Why Austin Aries and Raven Were At AEW Dynamite – PWMania

Mike Johnson of PWInsider.com noted the following regarding why Raven was sitting in the crowd during AEW Dynamite:

The Raven appearance looks to have been a red herring to make viewers think he is the exalted one when there are plans to go in another direction.

It appears that Austin Aries was backstage at AEW Dynamite in regards to Bioxcellerator, a stem cell therapy clinic that he serves as the Director of Athletic Performance Division. Aries gave the following statement to Bodyslam.net:

I did have meetings about partnerships and collaborations with both DDP and DDPY Brand as well as AEW.

View this post on Instagram

BIG ANNOUNCEMENT!!! . Many of you know that I went down to Medellin, Colombia in December for @bioxcellerator_ #stemcelltherapy, and now after a couple months, my neck and lower back feel really good. I was honestly so impressed with the entire @bioxcellerator_ operation. So much so, that upon returning I had conversations about joining the @bioxcellerator_ team in some capacity. . With that, I am EXTREMELY EXCITED TO ANNOUNCE that I have officially joined BioXcellerator as Director Of Athletic Performance Division. My role will be to continue connecting high level athletes, entertainers and influencers with all the amazing benefits of @bioxcellerator_ #stemcelltherapy. As someone whose passion is helping people, I couldnt pass up the opportunity to be a part of this company that is changing lives with their cutting edge #stemcelltherapy. . So, anyone whos been thinking about, or interested in finding out more about BioXcellerator stem cell therapy, Im your guy! Please DM or email me at Austin@BioXcellerator.com. Heres to all our improved health and happiness in 2020 and beyond! . . #bioxcellerator #bioxmen #bioxwomen #stemcell #stemcells #stemcelltherapy #medellin #colombia

A post shared by Austin Aries (@austinhealyaries) on Feb 17, 2020 at 8:49am PST

PWMania.com.com is recognized throughout the entire professional wrestling industry as one of the top sources for accurate and up-to-date professional wrestling news, rumors, and information.

The rest is here:
Why Austin Aries and Raven Were At AEW Dynamite - PWMania

Hyperbaric chamber therapy: Im under a lot of pressure and I love it! – The Guardian

I wonder what the pedalo does as I slip into a waffle robe Im at Bellecell, a central London molecular-wellness clinic that offers hyper-personalised science-based solutions to health this place could be a Bond villains laboratory on the moon.

I am standing in a hushed, blue-lit underground brick tunnel with Kubrick-white furnishings and so many fascinating toys: EMS suits, laser IVs, and what looks like an exercise bike built into a love boat, with a vacuum for your legs.

As distracting as these things are, I am here to try something specific: a hyperbaric oxygen chamber. I am fascinated by these things. Culturally, they have long been signifiers of megalomania, detachment and anxiety. Michael Jackson had one in his house, which isnt a great recommendation. The Olympian swimmer Michael Phelps is another fan. But what do these chambers actually do? Do you have to be called Michael to use one?

I climb into a plastic body bag in my hospital booties. Hyperbaric oxygen therapy involves breathing pure oxygen in a pressurised environment. The structure is a semi-circular cage with comfortable bedding, surrounded by thick plastic walls. Once I am inside, a technician inflates the bag. I am basically inside a balloon, which will be maintained at constant pressure, as I breathe 100% oxygen through a mask.

Hyperbaric chambers are mostly used to treat gas gangrene, carbon monoxide poisoning and the bends, while the medical uses of oxygen include wound-healing and reducing the risk of infection. Many people report feeling energised afterwards. I have some oral swelling following dental work, and am interested to see if that goes down.

For some, the close confinement and constant sound of pressurisation will be a recipe for a panic attack. For me, it is heaven. I am what you might call a claustrophile. I have always loved climbing into cupboards and corners, making dens and closing a door on the world. I fantasise about Japanese capsule hotels. Now, I lie and watch a zip close above me. There is a hissing noise. I adjust my oxygen mask and observe star-headed thumb screws being turned to calibrate the pressure. The gauge crawls upwards, my ears are getting stuffy. I swallow as it hits 4psi, equivalent to a depth of nine feet under water. Gazing at ambient blue through a hatch to the outside world, I imagine Im much deeper, packed into a nuclear missile on the undercarriage of a submarine. I am in my happy place.

The use of oxygen for performance-enhancement is mostly misunderstood. The effects of inhaling it are extremely short-lived. Athletes are often seen huffing cans of oxygen at the touchline, but science indicates that this is a mostly meaningless activity. Pressure makes all the difference. Under pressure, oxygen is dissolved in larger quantities in the blood plasma itself, not just the red blood cells. That means a much higher amount of the gas is transported into tissues that need it for healing, in theory mobilising stem cell release to repair the body quickly. It is definitely promising; the catch is, you would probably need a few treatments to see the benefit. At 160 an hour, post-workout muscle soreness probably isnt reason enough.

I thoroughly enjoy the experience for its own sake. Lulled by the pressure and soft lighting outside, I fall into a deep, restorative nap. After an hour, I emerge as wobbly as a newborn. I dont feel supercharged, admittedly. I feel drowsy, and absolutely starving. Im assured this is normal. I do feel astonishingly relaxed, though. The swelling inside my mouth reduces significantly over the next day, too, for which I can probably thank the chamber.

I would totally have one of these in my house. I miss the missile, but cant afford to go back. Instead, Im cursed to walk these normobaric streets, breathing 21% oxygen like everyone else, dreaming of when I had less freedom to move.

Walter White, eat your heart out Could I recreate the effect with hydrogen peroxide, bakers yeast and a tarp over the bath?

Wellness or hellness? Airs and graces. 5/5

View post:
Hyperbaric chamber therapy: Im under a lot of pressure and I love it! - The Guardian

Austin Aries Confirms Why He Was At AEW Dynamite This Week – 411mania.com

It was reported earlier this week that both DDP and Austin Aries were at this weeks AEW Dynamite taping, where it was rumored they were pitching a stem cell venture to the company.

Aries confirmed the story, noting that he works for the company Bioxcellerator, a stem cell therapy clinic.

He told Bodyslam.net: I work for BioX. I did have meetings about partnerships and collaborations with both DDP and DDPY Brand as well as AEW.

He previously revealed on Instagram that he joined the company as the Director of Athletic Performance Division.

View this post on Instagram

BIG ANNOUNCEMENT!!! . Many of you know that I went down to Medellin, Colombia in December for @bioxcellerator_ #stemcelltherapy, and now after a couple months, my neck and lower back feel really good. I was honestly so impressed with the entire @bioxcellerator_ operation. So much so, that upon returning I had conversations about joining the @bioxcellerator_ team in some capacity. . With that, I am EXTREMELY EXCITED TO ANNOUNCE that I have officially joined BioXcellerator as Director Of Athletic Performance Division. My role will be to continue connecting high level athletes, entertainers and influencers with all the amazing benefits of @bioxcellerator_ #stemcelltherapy. As someone whose passion is helping people, I couldnt pass up the opportunity to be a part of this company that is changing lives with their cutting edge #stemcelltherapy. . So, anyone whos been thinking about, or interested in finding out more about BioXcellerator stem cell therapy, Im your guy! Please DM or email me at [emailprotected] Heres to all our improved health and happiness in 2020 and beyond! . . #bioxcellerator #bioxmen #bioxwomen #stemcell #stemcells #stemcelltherapy #medellin #colombia

A post shared by Austin Aries (@austinhealyaries) on Feb 17, 2020 at 8:49am PST

Continued here:
Austin Aries Confirms Why He Was At AEW Dynamite This Week - 411mania.com

BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2019 Conference Call and Webcast @ 8:00 am Eastern…

NEW YORK, Feb. 18, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announces financial results for fiscal year ended December 31, 2019.

2019 was a tremendous year for BrainStorm, with significant progress and achievements across all clinical and operational fronts, stated Chaim Lebovits, President and Chief Executive Officer of BrainStorm. Most importantly, we fully enrolled our pivotal, double blind, placebo-controlled Phase 3 trial of NurOwn for the treatment of ALS. We announced the trial conducted at six major U.S. medical centers of excellence for ALS, was fully enrolled on October 11, 2019, and on October 28, 2019 the Data and Safety Monitoring Board (DSMB), completed the second planned interim safety analysis for the first 106 patients who received repeat dosing of NurOwn in the Phase 3 trial. The DSMB concluded the trial should continue as planned without any clinical protocol changes. He added, In addition, one of the most prestigious peer-reviewed journals, Neurology, published NurOwn Phase 2 Randomized Clinical Trial in ALS: Safety, Clinical and BioMarker Results, bringing news of our investigational therapy to the global scientific community. And, just last week, we were happy to announce that the Company recently held a high level meeting with the U.S. Food and Drug Administration (FDA) to discuss potential NurOwn regulatory pathways for approval in ALS.

Ralph Kern, MD, MHSc, Chief Operating Officer and Chief Medical Officer of BrainStorm added, 2019 was also a very significant year for those who suffer from progressive Multiple Sclerosis (MS). In February 2019, we announced Cleveland Clinic would serve as our first contracted site for a Phase 2 open-label, multicenter study of repeated intrathecal administration of NurOwn (autologous MSC-NTF cells) in participants with progressive MS (NCT03799718). We enrolled our first patient in March. We contracted with The Stanford University School of Medicine, The Keck School of Medicine of the University of Southern California, and the Mount Sinai Medical Center to further enroll patients. Dr. Kern added, The importance of our research in progressive MS was acknowledged by a $495,000 grant award from the National Multiple Sclerosis Society through its Fast Forward Program, and mid-December, the Data Safety Monitoring Board completed the first, pre-specified interim analysis, of safety outcomes for 9 participants and after careful review of all available clinical trial data, the DSMB unanimously concluded that the study should continue as planned without any protocol modification. As of December 31, 2019 we have enrolled 10 patients in the study (50% enrollment completed).

Fourth Quarter Corporate Highlights:

Financial Results for the Year Ended December 31, 2019 and Recent Updates

For further details on BrainStorms financials, including financial results for the year ended December 31, 2019, refer to the Form 10-K filed with the SEC today.

Conference Call on Tuesday, February 18th @ 8:00 am Eastern Time

The investment community may participate in the conference call by dialing the following numbers:

Those interested in listening to the conference call live via the internet may do so by visiting the Investors & Media page of BrainStorms website at http://www.ir.brainstorm-cell.com and clicking on the conference call link.

A webcast replay of the conference call will be available for 30 days on the Investors & Media page of BrainStorms website:

About NurOwnNurOwn (autologous MSC-NTF cells) represent a promising investigational approach to targeting disease pathways important in neurodegenerative disorders. MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors. Autologous MSC-NTF cells can effectively deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage to elicit a desired biological effect and ultimately slow or stabilize disease progression. NurOwn is currently being evaluated in a Phase 3 ALS randomized placebo-controlled trial and in a Phase 2 open-label multicenter trial in Progressive MS.

About BrainStorm Cell Therapeutics Inc.BrainStorm Cell Therapeutics Inc.is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwnCellular Therapeutic Technology Platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement as well as through its own patents, patent applications and proprietary know-how. Autologous MSC-NTF cells have received Orphan Drug status designation from theU.S. Food and Drug Administration(U.S.FDA) and theEuropean Medicines Agency(EMA) in ALS. Brainstorm has fully enrolled the Phase 3 pivotal trial in ALS (NCT03280056), investigating repeat-administration of autologous MSC-NTF cells at six sites in the U.S., supported by a grant from theCalifornia Institute for Regenerative Medicine(CIRM CLIN2-0989). The pivotal study is intended to support a BLA filing for U.S.FDAapproval of autologous MSC-NTF cells in ALS. Brainstorm received U.S.FDAclearance to initiate a Phase 2 open-label multi-center trial of repeat intrathecal dosing of MSC-NTF cells in Progressive Multiple Sclerosis (NCT03799718) inDecember 2018and has been enrolling clinical trial participants sinceMarch 2019. For more information, visit the company'swebsite.

Safe-Harbor StatementStatements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could causeBrainStorm Cell Therapeutics Inc.'sactual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorms need to raise additional capital, BrainStorms ability to continue as a going concern, regulatory approval of BrainStorms NurOwn treatment candidate, the success of BrainStorms product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorms NurOwn treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorms ability to manufacture and commercialize the NurOwn treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorms ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available athttp://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS

Corporate:Uri YablonkaChief Business OfficerBrainStorm Cell Therapeutics Inc.Phone: 646-666-3188uri@brainstorm-cell.com

Investor Relations:Preetam Shah, MBA, PhDChief Financial OfficerBrainStorm Cell Therapeutics Inc.Phone: 862-397-8160pshah@brainstorm-cell.com

Media:Sean LeousWestwicke/ICR PRPhone: +1.646.677.1839sean.leous@icrinc.com

BRAINSTORM CELL THERAPEUTICS INC.

CONSOLIDATED BALANCE SHEETSU.S. dollars in thousands(Except share data)

BRAINSTORM CELL THERAPEUTICS INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSSU.S. dollars in thousands(Except share data)

Continue reading here:
BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2019 Conference Call and Webcast @ 8:00 am Eastern...

Animal Stem Cell Therapy Market Projected to Witness Vigorous Expansion by 2017 2025 – Instant Tech News

The global Animal Stem Cell Therapy Market reached ~US$ xx Mn in 2019 and is anticipated grow at a CAGR of xx% over the forecast period 2017 2025. The business intelligence study of the Animal Stem Cell Therapy Market covers the estimation size of the market both in terms of value (Mn/Bn USD) and volume (x units).

In a bid to recognize the growth prospects in the Animal Stem Cell Therapy Market, the market study has been geographically fragmented into important regions that are progressing faster than the overall market.

Each market player encompassed in the Animal Stem Cell Therapy Market study is assessed according to its market share, production footprint, current launches, agreements, ongoing R&D projects, and business tactics. In addition, the Animal Stem Cell Therapy Market study scrutinizes the strengths, weaknesses, opportunities and threats (SWOT) analysis.

ThisPress Release will help you to understand the Volume, growth with Impacting Trends. Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) athttps://www.persistencemarketresearch.co/samples/14941

What insights readers can gather from the Animal Stem Cell Therapy Market report?

The Animal Stem Cell Therapy Market report answers the following queries:

Get Access To TOC Covering 200+ Topics athttps://www.persistencemarketresearch.co/toc/14941

Key Participants

The key participants in the animal stem cell therapy market are Magellan Stem Cells, ANIMAL CELL THERAPIES, Abbott Animal Hospital, VETSTEM BIOPHARMA, Veterinary Hospital and Clinic Frisco, CO, etc. The companies are entering into the collaboration and partnership to keep up the pace of the innovations.

The report covers exhaustive analysis on:

Regional analysis for Market includes

Report Highlights:

In order to get a strategic overview of the market,Access Research Methodology Prepared By Experts athttps://www.persistencemarketresearch.co/methodology/14941

Why Choose PMR?

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact us:

Persistence Market Research305 Broadway, 7th FloorNew York City, NY 10007United StatesPh.no. +1-646-568-7751

Read more:
Animal Stem Cell Therapy Market Projected to Witness Vigorous Expansion by 2017 2025 - Instant Tech News

6 Healthcare Stocks That Could Make You Filthy Rich – The Motley Fool

Picking home-run stocks -- or stocks capable of generating exponential returns on capital -- is no easy matter. That being said, there has arguably never been a more favorable environment for risk-tolerant investors on the hunt for unusual growth opportunities.

The fact of the matter is that the highly diversehealthcaresector has been churning out jaw-dropping returns on capital for the better part of the last decade.Companies like Axsome Therapeutics, for instance, have made a shocking amount of money for their early shareholders in an exceedingly short period of time. With this theme in mind, here is a look at six healthcare stocks that could make their early-bird investors filthy rich by the end of the current decade.

Image source: Getty Images.

Adaptimmune Therapeutics (NASDAQ:ADAP), a clinical-stage cancer immunotherapy company, has already gapped up by a staggering 235% so far this year. Investors have been taking notice of this small-cap biotech stock for two reasons. First off, Adaptimmune recently shored up its long-term financial health through a much-needed capital raise. Secondly, the biotech inked a lucrative partnering deal with the Japanese pharmaceutical giantAstellas to co-developnew stem-cell derived allogeneic T-cell therapies for people with cancer.

The main attraction here is the growing potential for Adaptimmune'saffinity-enhanced T-cell therapies to become a huge leap forward in the relatively new field of anti-cancer cell therapy. So, if that line holds, this small-cap biotech could rocket to large-cap status within just a matter of months. Adaptimmune's first major test will come with the next clinical update for its synovial sarcoma treatmentADP-A2M4. A positive readout should trigger more high-dollar licensing deals or perhaps even a buyout at a sky-high premium.

After a blistering 2019, Amarin (NASDAQ:AMRN), a mid-cap cardiovascular care company, has been a huge let down for investors during the early innings of 2020. The big-ticket item is the company's omega-3 treatment Vascepa, which was recently awarded a broader label as an add-on to statin therapy in patients with stubbornly high triglyceride levels and who are at risk of a heart attack, stroke, and certain types of heart issues requiring hospitalization.

Long story short, some investors bought the stock on the hope and belief that a high-dollar buyout was imminent in the wake of Vascepa's successful label expansion. Vascepa, after all, has a shot at one day posting multi-billion-dollar-a-year sales. Unfortunately, a buyout has yet to materialize.

But that doesn't mean that investors should throw in the towel. In the not-so-distant future, most industry insiders do expect Vascepa to at least reach blockbuster status (greater than $1 billion in annual sales). So, whether or not a suitor ever emerges, Amarin's equity should turn out to be a big winner for patient shareholders.

Canadian pot titan Aphria (NYSE:APHA) has also been a big disappointment for investors in 2020. Through no fault of its own, Aphria's shares have shed more than 17.4% of their value during the first six weeks of the new year. The key issue weighing down the pot company's stock is the dismal near-term outlook for the legal cannabis space at large. Canada's legal pot market has suffered from structural and regulatory setbacks, as well as the slow pace of legalization in the international arena. Nonetheless, Aphria could turn out to be a hidden gem.

Unlike most of its cannabis peers, Aphria has been able to attractdeep-pocketed investors this year, it has been turning a profit on a consistent basis, and it also has a fairly healthy cash runway. So, even though 2020 will probably be another tough year for pot stocks in general, Aphria's low-ball valuation and various competitive advantages over the broader field arguably make it one of the few compelling buys in this space right now. In fact, it wouldn't be surprising if Aphria morphed into a blue-chip company by the end of the decade.

The U.K. based drugmaker Bicycle Therapeuticsplc (NASDAQ:BCYC) has all the hallmarks of a hidden gem. The company's proprietary bicyclic peptide technology, or Bicycle for short, has the potential to push the field of immuno-oncology to new heights within a few short years. That being said, Bicycle is a highly speculative bet at this early stage of the game.

Point blank, the company's novel anti-cancer platform has yet to be validated via a large dataset in human subjects. Bicycle's highly differentiated immuno-oncology pipeline, though, is just the type of drug development platform that tends to attract blue-chip partners. As a result, investors comfortable with heavy doses of risk may want to get in on the ground floor of this unique immunotherapy company. After all, Bicycle's stock will surely catch fire at some point if its bicyclic peptide technology continues to hit the mark in the clinic.

Novavax (NASDAQ:NVAX) is a late-stage vaccine developer. Although the biotech's shares have been getting a boost from the COVID-19 threat of late, the real reason to consider this small-cap stock is the company's experimental flu vaccine known as NanoFlu. NanoFlu has the potential to reach blockbuster status perhaps within its first full year on the market due to the dire need for more effective flu vaccines. The company is expected to release the vaccine's pivotal stage results by the end of the first quarter.

What's the risk? Novavax has repeatedly rolled out promising early-to-mid-stage results for its vaccine development platform. However, the company has a poor track record when it comes to late-stage trials, which is likely the underlying reason its current valuation stands at a tiny fraction of NanoFlu's commercial opportunity right now.

In effect, the market doesn't have much confidence that Novavax will hit pay dirt with NanoFlu. So, if the company does prove its critics wrong this time around, its shares could quite possibly quadruple in value in the blink of an eye. Again, though, the high degree of risk with this name shouldn't be ignored. This clinical-stage biotech stock is basically an all-or-nothing value proposition at this critical juncture in its lifecycle.

Puma Biotechnology (NASDAQ:PBYI), a small-cap cancer specialist, has been blazing the comeback trail in 2020. The drugmaker's shares have gained a healthy 40% so far this year due to the growing optimism surrounding the commercial prospects of its much-maligned breast cancer treatmentNerlynx.Nerlynx's real-world commercial opportunity has basically been shrouded in mystery since its launch. The core issue is that the drug tends to produce severe bouts ofdiarrhea, which has led to uncomfortably high discontinuation rates among patients. The drug's sales, in turn, have consistently missed Wall Street's consensus estimates by a country mile ever since its commercial debut.

The market's extremely pessimistic take on this biotech stock, though, appears to be overdone at this point. Puma's shares are now trading at a dirt cheap price-to-sales ratio of 1.71. Most cancer specialists are currently garnering premiums that are four to five times higher. Puma's stock may ultimately fail to launch due to Nerlynx's problematic side effect profile.But there's also a decent chance that the biotech's clearance-rack valuation might attract one or more suitors before year's end. This grossly undervalued biotech could thus turn out to be the comeback story of the year.

Read this article:
6 Healthcare Stocks That Could Make You Filthy Rich - The Motley Fool

Mixed ethnic backgrounds make it that much harder to find a bone marrow transplant – MLive.com

ANN ARBOR, MI They searched the world for a match.

Bennett Sevack needed a bone marrow transplant. He was diagnosed with myelodysplastic syndrome after treatment for chronic lymphocytic leukemia. But there was no match for the Ann Arbor resident in the international registry.

So, his family started making calls.

Doctors first tried his siblings and cousins. When that didnt work, his sisters, friends and family spent six weeks calling and sharing flyers with synagogues around the world to encourage people to join the bone marrow registry, hoping someone with Sevacks Sephardic and Ashkenazi Jewish background would be willing to donate.

By fall, a partial match was found in an Italian obstetrics hospital in an umbilical cord blood sample. Soon after, another cord blood match was found in the U.S. It was enough to perform a transplant.

Sevack has gained an intense appreciation for donors.

You can save somebodys life..." he said. Its a blessing to do.

Finding an acceptable bone marrow donor is a challenge in general, but its that much harder for people of color and patients of complex ethnic backgrounds like Sevack, according to health care providers and families whove embarked on far-reaching searches for a match.

A white person has a 77% shot at finding a matching donor, according to Be The Match, a widely used donor registry. A black persons chances are 23%. For people of mixed backgrounds, the search can become more complex.

Part of the issue is the relatively narrow population of donors in the registry. Another part is the science: Certain HLA types, the protein that needs to match in bone marrow transplants, are more unique to specific backgrounds.

A closer look at plans for the new $920M University of Michigan hospital

Sevacks transplant was completed in October 2019 more than three years after his initial diagnosis, and four months after getting news that he would definitely need a transplant.

He spent eight weeks healing from his transplant and two weeks healing from a bout of graft-versus-host disease in the hematology oncology clinic on the seventh floor of Ann Arbors C.S. Mott Childrens Hospital.

On the same floor, a 9-year-old Ann Arbor-area patient undergoing chemotherapy for acute myeloid leukemia is in the same predicament that Sevack once faced. She may need a bone marrow transplant as well, but a donor match her ethnic background is Cantonese, Hispanic and Caucasian has yet to be found in the registry.

The search

Genetics play a major role in finding a good match, said Mark Vander Lugt, a pediatric bone marrow transplant specialist at C.S. Mott working with the 9-year-old. People get four HLA types from each parent, meaning donors need to match in at least six spots, though sometimes a stronger match is required.

You get combinations that are hard to find in the registry because of that, Vander Lugt said.

Not everyone needs a transplant once theyre diagnosed. Doctors often treat blood cancers and related illnesses with chemotherapy first killing off the bad cells and waiting to see if healthy cells regenerate. If they dont, a transplant replaces the bone marrow, where blood stem cells are made.

Mothers breast cancer pushes Ypsilanti woman to get preventative mastectomy

The registry is so low on certain populations that some began taking matters into their own hands. Athena Asklipiadis founded Mixed Marrow, a nonprofit that conducts outreach to encourage multi-ethnic bone marrow and blood cell donations. She said the misconceptions of donation is one of the largest challenges in getting people registered. She started by reaching out to Facebook groups and college clubs on the West Coast, where she is based. Eventually, families began reaching out to her to help in the donor search.

People use this phrase, When theres a cure for cancer or If theres a cure for cancer, Asklipiadis said. But these are actual blood diseases and cancers that are curable. Theyre curable by the selflessness of a donor and thats the beautiful thing about it.

Sevacks sister Laurel Bernstein was part of the group of relatives and supporters who called synagogues in search of donors. She estimated they called hundreds of people and added more than 1,000 to the donor registry while searching for Sevacks match.

The nine of us all felt so energized by what happened, Bernstein said. "We had not finished calling the list, even though we got the match. We went through to the end of the list to help pay it forward, to help other people, to get that much more DNA into the database.

The transplant

For Sevack, it was umbilical cord blood that saved his life. DNA from the two samples created enough HLA type matches to begin the transplant.

Vander Lugt said the preferred transplant method is still donor transplants, because cord blood units are smaller and in more limited supply than donor cells.

Misconceptions of transplants are another roadblock. A bone marrow harvest in which a donor undergoes surgery to collect marrow from the hip is widely believed to be painful. But experts describe the process as a mild discomfort with a two-to-three day recovery time, instead.

And direct harvest is no longer the only method. Many hospitals also practice apheresis, which collects the peripheral blood that can generate new bone marrow through a process that looks like dialysis. Theres no surgery involved.

Choosing between the two collection processes is based on multiple factors, including the health of the patient undergoing general anesthesia and doctor and donor preference, Vander Lugt said.

The value

Fear of the unknown is what affected Sevack the most going into treatment. He said he had an anxiety breakdown the morning of his transplant, when he realized what was about to happen.

My heart was to the moon, Sevack said. I was fully dressed and every part of me was drenched. In about eight minutes I had gone through this journey of fear because the reality of what was going to come was upon me. (My wife) calmed me down, I changed my clothes and this journey began. Theres been plenty of times when Ive been scared to death.

Finding a transplant match taught his wife Phyllis Sevack the importance of facing each day separately. Fighting cancer was about healing every day making big battles smaller.

The reality of it hits all at once, Phyllis Sevack said. "I wouldnt want anybody to be afraid to go through it because it is every day take it day by day. And as soon as Bennett got over that hes not doing everything on one day, (he got better mentally).

Now at home, Bennett Sevack may take a year to fully heal. He looks forward to small improvements in his quality of life, like an expanded diet and doing his own grocery shopping at Meijer, he said.

Even the routine blood and platelet donations he received in treatment were invaluable to him. They saved his life.

Where to donate blood in Washtenaw County during shortage

Every day, theyd give me sacks of stuff that made me sick to think about it, Sevack said. It was someones donation that was given, that was literally giving me life. People who donate would do an amazing service to someone. You may not know who that is but its somebody.

Potential donors can begin the registration process by filling out a questionnaire about their medical history at bethematch.org. A cheek swab will confirm whether you meet the medical guidelines for donation. You may remain on the registry for years before a match is found. More information is available here.

Wolverines for Life and the Michigan Medicine Bone Marrow Transplant department are hosting a registration drive from 10:30 a.m. to 5 p.m. Tuesday, Feb. 18 at the Pierpoint Commons lobby, 2101 Bonisteel Blvd., Ann Arbor.

See the original post here:
Mixed ethnic backgrounds make it that much harder to find a bone marrow transplant - MLive.com

48% of Couples Are Making This Financial Mistake – Nasdaq

"Now it's true I married my wife for her looks ... but not the ones she's been giving me lately."

-- Comedian Jeff Foxworthy

If you've been sharing raised eyebrows and evil stares with your spouse lately, a financial disagreement is a likely cause. Money is routinely cited as a common source of friction between spouses, but there are steps you can take to change that.

A 2019 survey by Northwestern Mutual and wedding planning website The Knot questioned married folks on their views about money and budgeting. Some 40% of those respondents cited financial stability as their greatest long-term worry, making it a more prominent concern than raising children and maintaining intimacy in their relationship. But surprisingly, 48% of respondents said they weren't reviewing finances weekly with their spouse. And 22% admitted to having budgeting disagreements with their partner each month.

Image source: Getty Images.

An open line of communication between spouses about money can head off arguments by ensuring both partners are on the same page about their money and financial goals. Here are five essential strategies to kick off money-planning sessions with your spouse.

Start your money talks by sharing and prioritizing long-term financial goals. An obvious starting point is retirement. Discuss how each of you envisions life after work. Then address other common goals, such as funding college for the kids or buying a new home. Keep the conversation going to talk through "wish list" goals, too. Is there the chance one of you might start a business in the future? Does your spouse secretly want to buy a boat someday? Nothing is off the table.

Write down these goals and, together, rank them in priority. Next, you'll build a budget to start moving toward those goals.

Budgeting begins with knowing what your lifestyle costs you today. Write down all of your shared and required expenses. These include rent or mortgage payments, property taxes, utilities, food, car payments, gas, and insurance.

Ideally, these should total about 50% of your combined take-home pay. If the percentage is higher than that, explore ways to reduce your costs. Often, food is the easiest place to trim spending: You could start cutting coupons or only buy items that are on sale, for example. If you need to make larger cuts, brainstorm what's possible. Could you move to a cheaper neighborhood, downsize your cars, or bundle your insurance plans to save?

Discretionary spending can be a point of contention for couples. Maybe your spouse spends $200 monthly on streaming services plus cable, while you'd be happy with a $10 monthly subscription to Kindle Unlimited. There is no universal solution to solve these differences, but you can and should define a system that works for the two of you.

If you have your required expenses down to 50% of your combined take-home pay, you can afford to spend another 30% on nonessentials. Split that 30% up in whatever way makes sense for your situation. Most of the time, it's logical to allocate 10% to each of you and 5% to shared discretionary expenses. In this framework, you each can make nonessential buying decisions as long as you stay within your 10%.

For this system to work, you'll have to talk through which expenses belong to you and which belong to your partner. If you both go to the gym, for example, that's a shared expense. But other items, like cable, may not be clear-cut. Perhaps your spouse feels strongly about having access to HGTV and you are indifferent to cable. If your spouse takes responsibility for that bill, it doesn't mean you must look away whenever House Hunters is on.

The goal isn't to be territorial. It's to provide a framework that gives each of you some financial decision-making rights within the relationship. If you play within the rules, you can each spend on things that are important to you.

At this point, you've allocated 50% of your take-home pay to required expenses and 30% to the nonessentials. That leaves 20% available for debt payments and long-term financial goals. Experts recommend you save 15% to your retirement accounts. Of course, if you have high debt levels or other financial goals to fulfill before retirement, that 15% may not be possible. Save at least enough to your 401(k) to maximize your company-match contributions and decide together how to allocate the rest.

Now comes the hard part. Set a recurring day and time for the two of you to review your spending. The first few sessions will probably reveal some holes in your budget and some misunderstandings about what's a shared expense and what's not. That's part of the process. Make adjustments to the budget and your spending rules until you land on a system that's sustainable. Remember that the two of you are on the same team, working toward the same list of prioritized goals.

There's one final rule about these money-planning sessions: Leave the cold stares at the door. You'll both make spending mistakes and together you'll face unexpected expenses. Don't let these derail you from your shared plan. Just rework the budget and keep pressing on toward those long-term goals.

The $16,728 Social Security bonus most retirees completely overlook If you're like most Americans, you're a few years (or more) behind on your retirement savings. But a handful of little-known "Social Security secrets" could help ensure a boost in your retirement income. For example: one easy trick could pay you as much as$16,728 more... each year! Once you learn how to maximize your Social Security benefits, we think you could retire confidently with the peace of mind we're all after.Simply click here to discover how to learn more about these strategies.

The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Read the original post:
48% of Couples Are Making This Financial Mistake - Nasdaq

‘Loving life’: 4-year-old not letting heart condition slow him down – Port Clinton News Herald

Buy Photo

Lucas Gutman, 4, listens along as Port Clinton City Council President Lisa Sarty reads an official proclamation from the city recognizing Conquering Congenital Heart Defect Week.(Photo: Jon Stinchcomb/News Herald)

PORT CLINTON - Though four years ago he was born with a condition making his heart critically underdeveloped, Lucas Gutman does not let it slow him down one bit.

In fact, Lucas is every bit as active as you would expect of a typical toddler and you would never know he was a child living with a congenital heart defect.

Hes playing soccer. He has tons of friends, said Jennifer Gutman, Lucas mother. Hes living life. Hes loving life.

His grandfather said Lucas has no shortage of energy. That was readily apparent when Lucas came to Port Clinton City Hall this week to be honored with an official proclamation.

The proclamation declared this week Conquering Congenital Heart Defect Week in the City of Port Clinton.

Lucas Gutman, 4, holds an official proclamation in honor of him from the City of Port Clinton. Gutman was diagnosed with hypoplastic left heart syndrome as an infant, but he does not let that slow him down.(Photo: Jon Stinchcomb/News Herald)

It coincides with a national week-long movement to raise awareness of what is actually a common but not widely known medical condition, congenital heart defects, or CHD.

Each year, the American Heart Association sponsors the Congenital Heart Defect Awareness Week from Feb. 7 to 14, an effort to encourage increased education about CHDs.

According to the federal Centers for Disease Control and Prevention, one in 100 babies are born with a heart defect, the most common type of birth defect. Annually, twice as many children die from congenital heart defects than all forms of childhood cancer combined.

Jennifer Gutman said she is so thankful to the city for the proclamation and efforts to raise awareness of CHD.

With awareness comes funding that we desperately need, she said. This is the Port Clinton that I know and love. The community that comes together for each other and Im very proud to be a citizen of Port Clinton.

The Gutman family has experienced the love of the close-knit local community before.

Lucas Gutman, of Port Clinton, was born in 2015 with hypoplastic left heart syndrome, meaning the left side of his heart was underdeveloped.(Photo: Submitted)

After Lucas was born and diagnosed, thanks to a fundraiser organized by the Port Clinton Fire Department, their very first Firelight Fund 5K glow run, the family was able to travel to Minnesota to participate in a clinical research trial at the Mayo Clinic in Rochester.

More: Firelight Fund to help local family as child battles rare disease

The form of CHD that Lucas was diagnosed with is hypoplastic left heart syndrome, or HLHS, which means the left side of the heart is critically underdeveloped.

According to the Mayo Clinic, typical treatment for HLHS usually involves medication, multiple surgeries, and can, in some cases, include a heart transplant.

However, the Mayo Clinics lead researcher on their Hypoplastic Left Heart Syndrome Program, Dr. Timothy Nelson, has been studying regenerative therapies like stem cell injections for treating HLHS.

The Gutman family decided to participate in the clinical trial and in December 2015, Lucas became the second child in the country to receive a stem cell injection from his own umbilical cord blood.

Since then, the results have been incredibly promising for Lucas.

His cardiologist is now saying that she wishes she could prescribe stem cells to all of her HLHS patients, Jennifer said. Hes doing great.

The Gutman family is taking it one step at a time as Lucas continues to live life like any other fun-loving toddler.

What the next 10-to-20 years will bring, we dont know yet, Jennifer said. But were faithful and we trust that hes going to show everybody what you can make happen with CHD. Were very proud of him.

Lucas Gutman, 4, listens along as Port Clinton City Council President Lisa Sarty reads an official proclamation from the city recognizing Conquering Congenital Heart Defect Week.(Photo: Jon Stinchcomb/News Herald)

jstinchcom@gannett.com

419-680-4897

Twitter: @JonDBN

Read or Share this story: https://www.portclintonnewsherald.com/story/news/2020/02/14/port-clinton-4-year-old-not-letting-heart-condition-slow-him-down/4759021002/

View original post here:
'Loving life': 4-year-old not letting heart condition slow him down - Port Clinton News Herald